The Summary
In a 60-week double-blind randomized controlled trial, 120 adults with overweight or obesity received either semaglutide 2.4 mg or a placebo. Researchers measured calorie intake during laboratory lunches and tracked subjective appetite. While the semaglutide group consistently ate significantly fewer calories than the placebo group at weeks 20, 40, and 60 (averaging 240 to 292 fewer calories), their subjective feelings of appetite suppression and reduced hunger faded by week 40. This suggests the drug continues to limit calorie intake through mechanisms beyond conscious feelings of fullness.
Why this is interesting
Previously, scientists believed semaglutide's benefits relied entirely on ongoing appetite suppression. This study shows that while subjective feelings of fullness and reduced hunger fade over time, the biological drive to consume fewer calories persists. For patients, this is highly encouraging: it explains why the drug remains effective for long-term weight maintenance even if you start feeling 'normal' hunger again. It suggests the medication quietly alters energy intake and food reward pathways in the brain, working behind the scenes to prevent overeating regardless of conscious appetite.